Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 12:16 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 3,759 matching trials from the live ClinicalTrials.gov search.
Conditions
Bladder Cancer, Glioma, Glioblastoma (GBM), Breast Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer (GC), Pharynx Cancer, Oral Cavity Cancer, Kidney Cancer, Liver Cancer, Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, Prostate Cancer
Interventions
[64Cu]CM500, [68Ga]CM500, PET/MR, PET/CT, Blood Collection
Drug · Device · Procedure
Lead sponsor
Lumina Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
3
States / cities
Boston, Massachusetts • Grand Rapids, Michigan • New York, New York
Conditions
Metastatic Esophageal Carcinoma, Metastatic Gastric Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Gastroesophageal Junction Adenocarcinoma, Stage III Esophageal Cancer AJCC v7, Stage III Gastric Cancer AJCC v7, Stage IV Esophageal Cancer AJCC v7, Stage IV Gastric Cancer AJCC v7, Unresectable Esophageal Carcinoma, Unresectable Gastric Carcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
Interventions
Olaparib, Ramucirumab
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
32
States / cities
Corona, California • Duarte, California • Lancaster, California + 24 more
Conditions
Cervical Cancer, Advanced Cervical Carcinoma, Metastatic Cervical Cancer, Metastatic Cervical Carcinoma, Recurrent Cervical Carcinoma
Interventions
Dostarlimab, Cobolimab
Drug
Lead sponsor
Meghan Shea
Other
Eligibility
18 Years and older · Female only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Oral Squamous Cell Carcinoma
Interventions
PRV111 (Cisplatin Transmucosal System)
Drug
Lead sponsor
Privo Technologies
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
5
States / cities
Louisville, Kentucky • Cincinnati, Ohio • Houston, Texas
Conditions
Laryngeal Squamous Cell Carcinoma, Stage II Laryngeal Cancer AJCC v8, Stage III Laryngeal Cancer AJCC v8
Interventions
Carboplatin, Cisplatin, Docetaxel, Pembrolizumab
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Houston, Texas
Conditions
Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck
Interventions
Panitumumab, Zirconium Zr 89 Panitumumab, Positron Emission Tomography, Computed Tomography, Electronic Health Record Review
Biological · Drug · Procedure + 1 more
Lead sponsor
Eben Rosenthal
Other
Eligibility
19 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Interventions
Tumor-Informed ctDNA Assessment (Signatera™ Genome Assay)
Diagnostic Test
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Non Small Cell Lung Cancer, Bladder Cancer, Renal Cell Carcinoma, Melanoma, Head and Neck Cancer, Colorectal Cancer
Interventions
PF-07921585, Sasanlimab
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
9
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 4 more
Conditions
Head and Neck Cancer
Interventions
Everolimus, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 89 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Chicago, Illinois • Evanston, Illinois
Conditions
Head and Neck Carcinoma, Hypopharyngeal Carcinoma, Laryngeal Carcinoma, Oral Cavity Carcinoma, Oropharyngeal Carcinoma
Interventions
Electronic Health Record Review, Fentanyl, Laryngoscopy, Methadone, Surgical Procedure, Survey Administration
Other · Drug · Device + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 89 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Thyroid Nodules, Hypocalcemia
Interventions
Calcitriol, Control Pill
Dietary Supplement
Lead sponsor
David Shonka, MD
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Squamous Cell Carcinoma of Hypopharynx, Squamous Cell Carcinoma of Larynx, Squamous Cell Carcinoma of Oropharynx, Squamous Cell Carcinoma of Oral Cavity
Interventions
Scheduled IV Hydration, Clinician Assessment-Based IV Hydration
Other
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
6
States / cities
Bridgeport, West Virginia • Martinsburg, West Virginia • Morgantown, West Virginia + 3 more
Conditions
RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer, RET-altered Colon Cancer, RET-altered Solid Tumors, Lung Neoplasm, Carcinoma, Non-Small-Cell Lung, Thyroid Diseases, Thyroid Neoplasm, Thyroid Cancer, Papillary, Carcinoma, Neuroendocrine, Respiratory Tract Neoplasms, Thoracic Neoplasms, Neoplasms by Site, Neoplasms, Lung Diseases, Respiratory Tract Disease, Carcinoma, Bronchogenic, Bronchial Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasm, Head and Neck Neoplasms, Adenocarcinoma, Papillary, Adenocarcinoma, Carcinoma, Neoplasms, Glandular and Epithelial, Neoplasms by Histologic Type, Neuroendocrine Tumors, Neuroectodermal Tumors, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Colonic Neoplasms, Colorectal Neoplasms, Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasm, Digestive System Disease, Gastrointestinal Disease, Colonic Diseases, Intestinal Disease
Interventions
pralsetinib (BLU-667)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
18
States / cities
Phoenix, Arizona • Orange, California • Aurora, Colorado + 15 more
Conditions
Head and Neck Cancer
Interventions
Oxaliplatin, Radiation
Drug · Procedure
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Orange, California
Conditions
Cervical Cancer, Endometrial Cancer, Ovarian Cancer
Interventions
topical gemcitabine hydrochloride, therapeutic conventional surgery
Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Parotid Salivary Dysfunction
Interventions
Gene Transfer, AdhAQP1
Genetic · Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Squamous Cell Carcinoma of the Head and Neck (SCCHN), Ovarian Carcinoma-Enrollment Completed, Colorectal Cancer (CRC)-Enrollment Completed, Renal Cell Carcinoma (RCC) (Phase ll Only), Glioblastoma (GBM) (Phase ll Only)-Enrollment Completed
Interventions
Combination of varlilumab and nivolumab
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
19
States / cities
Tucson, Arizona • Palo Alto, California • San Francisco, California + 13 more
Conditions
Solid Tumors
Interventions
DB-1311/BNT324, BNT327, DB-1305/BNT325
Drug
Lead sponsor
DualityBio Inc.
Industry
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
15
States / cities
Los Angeles, California • Wheat Ridge, Colorado • Florida City, Florida + 11 more
Conditions
Head and Neck Cancer
Interventions
recombinant interferon alfa, vitamin E, isotretinoin, adjuvant therapy
Biological · Dietary Supplement · Drug + 1 more
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
82
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 57 more
Conditions
Breast Cancer, Head and Neck Cancer, Diffuse Large B-cell Lymphoma
Interventions
PET/CT, Laboratory Testing, Safety Testing, Immunohistochemistry staining, F-18-ISO
Radiation · Other · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma
Interventions
mRNA-2752, Durvalumab
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
16
States / cities
San Francisco, California • Santa Monica, California • Aurora, Colorado + 10 more
Conditions
Non-Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Ovarian Cancer
Interventions
PF-07257876
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
39
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Fayetteville, Arkansas + 25 more
Conditions
Head and Neck Cancer
Interventions
oxaliplatin, pemetrexed disodium
Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
7
States / cities
Owensboro, Kentucky • Paducah, Kentucky • Jackson, Tennessee + 1 more
Conditions
Cervical Cancer
Interventions
Sacituzumab Tirumotecan, Pemetrexed, Tisotumab Vedotin, Topotecan, Vinorelbine, Gemcitabine, Irinotecan
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
686 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
38
States / cities
Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 35 more